Skip to content

ΕτικέταNSCLC

Takeda’s Alunbrig Shows Superiority Over Pfizer’s Xalkori in Some Lung Cancer Patients

  Takeda Pharmaceutical‘s Alunbrig (brigatinib) hit its Phase III primary endpoints of statistically significant improvement in progression-free survival compared to crizotinib (Pfizer’s Xalkori) in a subset of lung cancer patients following the first pre-specified … Continue Reading Takeda’s Alunbrig Shows Superiority Over Pfizer’s Xalkori in Some Lung Cancer Patients

Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer

Imfinzi met the second primary endpoint of overall survival which was both statistically-significant and clinically-meaningful at a planned interim analysis AstraZeneca and MedImmune, its global biologics research and development arm, … Continue Reading Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer